Royce & Associates LP Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Royce & Associates LP reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 29.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 124,011 shares of the biopharmaceutical company's stock after selling 52,716 shares during the quarter. Royce & Associates LP owned about 0.10% of Halozyme Therapeutics worth $7,098,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Boston Trust Walden Corp bought a new position in shares of Halozyme Therapeutics in the second quarter worth $23,211,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Halozyme Therapeutics by 29.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company's stock valued at $5,321,000 after acquiring an additional 29,845 shares during the last quarter. Swedbank AB purchased a new position in shares of Halozyme Therapeutics during the first quarter worth about $13,927,000. Creative Planning increased its position in shares of Halozyme Therapeutics by 43.2% in the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company's stock worth $1,953,000 after purchasing an additional 11,249 shares during the last quarter. Finally, Boston Partners raised its stake in Halozyme Therapeutics by 14.1% in the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company's stock valued at $25,500,000 after purchasing an additional 77,976 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 70,000 shares of company stock valued at $4,042,500 in the last three months. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. The Goldman Sachs Group upped their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a "neutral" rating in a report on Monday, July 22nd. Benchmark reissued a "buy" rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, TD Cowen upped their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Stock Down 6.7 %

Shares of HALO traded down $3.08 on Monday, reaching $42.57. The stock had a trading volume of 5,482,611 shares, compared to its average volume of 1,341,916. The company has a 50-day simple moving average of $56.04 and a 200-day simple moving average of $53.48. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of 14.10, a price-to-earnings-growth ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.